clopidogrel – Medxy AI

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation

By MedXY 05/09/2026

This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.

Cardiology news

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis

By MedXY 10/11/2025

This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.

Cardiology Clinical Updates news

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Cardiology news Specialties

Clopidogrel Surpasses Aspirin: Comprehensive Meta-Analysis Shows Superior Secondary Prevention in Coronary Artery Disease

By MedXY 09/02/2025

A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.

Cardiology Nephrology Specialties

Comparative Effectiveness of Prasugrel Versus Clopidogrel in Patients with Impaired Renal Function: A Clinical Review

By MedXY 08/21/2025

Prasugrel demonstrates a more rapid and significant inhibition of platelet aggregation than clopidogrel in patients with stable coronary artery disease and impaired renal function, particularly within the first week of therapy.